成都科创板上市公司欧林生物 发布公告显示 公司在香港联交所主板上市的备案申请材料 11月12日晚间 欧林生物成立于2009年，是一家专注于人用疫苗研发、生产及销售企业，实现三款产品的商业化：吸附 破伤风疫苗、b型流感嗜血杆菌结合疫苗（或Hib结合疫苗）及A群C群脑膜炎球菌多糖结合疫苗（或AC 结合疫苗）。此外，公司还正在积极探索开发"超级细菌"——重组金黄色葡萄球菌疫苗研发，这是国际 上靶标组分最多且唯一进入Ⅲ期临床试验的同类疫苗。 2021年6月，公司成功在上交所科创板上市。上市以来，公司在首年即实现盈利，2022年-2024年公司营 收分别为5.47亿元、4.94亿元、5.86亿元；毛利分别为5亿元、4.6亿元、5.51亿元；期内利润分别为2658 万元、1144万元、1572万元。今年前三季度，营收为5.07亿元，同比增长31.11%；净利为4748万元。 对于赴港上市的原因，欧林生物表示，为加快公司的国际化战略及海外业务发展，增强公司的境外融资 能力，进一步提高公司的综合竞争力。同时，为有效拓展海外市场，提升国际影响力，推进公司长远战 略的实施，公司拟以自有资金出资不超过港币10000元，在香港设立全 ...

转自：成都日报锦观 上市申请获受理 成都"超级细菌"概念股冲刺港股IPO 1月12日晚，成都科创板上市公司欧林生物发布公告显示，公司在香港联交所主板上市的备案申请材 料，已于近日获中国证监会接收。这意味着，公司距离港股上市再进一步。 欧林生物成立于2009年，是一家专注于人用疫苗研发、生产及销售的企业，实现三款产品的商业化：吸 附破伤风疫苗、b型流感嗜血杆菌结合疫苗（或Hib结合疫苗）及A群C群脑膜炎球菌多糖结合疫苗（或 AC结合疫苗）。此外，公司还正在积极探索开发"超级细菌"——重组金黄色葡萄球菌疫苗研发，这是 国际上靶标组分最多且唯一进入Ⅲ期临床试验的同类疫苗。 在此背景下，成都正深化蓉港资本市场互联互通，成都企业奔赴港股市场的步伐也正在加快。随着科伦 博泰生物、茶百道等公司成功登陆港交所，来自成都的港股上市公司已达29家。此外，极米科技、天味 食品等一批生物医药、高新科技、食品消费类企业正计划通过"A+H"战略走向更广阔的市场。在港上市 的"成都军团"有望随之扩容。 成都日报锦观新闻记者 刘泰山 2021年6月，公司成功在上交所科创板上市。上市以来，公司在首年即实现盈利，2022—2024年营收分 别为 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 成都欧林生物科技股份有限公司（以下简称"公司"）已于2023年12月与科园信海（北京）医疗用品贸 易有限公司（以下简称"科园贸易"）在全国范围内进行公司A群C群脑膜炎球菌多糖结合疫苗（以下简 称"AC结合疫苗"）的市场推广服务达成一致并签署协议。 ● 为持续深化稳定、长期的合作关系，基于双方对市场环境的共同研判，经友好协商，公司与科园贸易 签署了《A群C群脑膜炎球菌多糖结合疫苗市场推广服务协议之补充协议》，对原协议有效期进行优化 调整，其他核心条款保持不变。 ● 对上市公司当期业绩的影响：该协议的签署预计不会对公司当期经营业绩产生重大影响。 ● 合同履行中的重大风险及重大不确定性：本协议约定的推广任务量并不等于实际销量，不构成业绩承 诺，具体的销售情况存在不确定性。本协议受市场环境变化、法律法规等影响，可能存在双方不能继续 履约的风险，公司将根据相关规则的要求及时披露协议进展情况。敬请广大投资者注意相关风险。 一、协议的签署概况 公司已于2023年12月与 ...

证券日报网讯1月5日，沃森生物（300142）在互动平台回答投资者提问时表示，目前公司共有8个自主 疫苗产品(14个品规)正式上市销售，包括：13价肺炎结合疫苗(西林瓶型和预灌封型)、双价HPV疫苗(西 林瓶型和预灌封型)、23价肺炎多糖疫苗(西林瓶型和预灌封型)、b型流感嗜血杆菌结合疫苗(西林瓶型和 预灌封型)、A群C群脑膜炎球菌多糖结合疫苗(西林瓶型和预灌封型)、ACYW135群脑膜炎球菌多糖疫苗 (西林瓶型和预灌封型)、A群C群脑膜炎球菌多糖疫苗(西林瓶型)和吸附无细胞百白破联合疫苗(西林瓶 型)。上述疫苗产品主要用于预防由特定病原微生物感染所引起的相关疾病。公司将持续狠抓产品营销 工作，制定切实可行的策略和执行措施，加强人才队伍建设，以科学普及为助力，坚定信心，强化落 实，努力加强和巩固终端渠道的覆盖率和渗透率，为公司和股东创造价值。 ...

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. is currently facing a legal dispute regarding two core vaccine products, leading to the freezing of some bank accounts by the court, which may impact the company's financial performance and operations [2][3]. Legal Dispute - The company received a lawsuit notification from the Chengdu Intermediate People's Court, where the plaintiff, Wang Jianhua, is demanding a total of 16 million yuan in commissions and an additional 3.2 million yuan in penalties related to vaccine products [2]. - Wang claims to have provided all technical materials for two vaccines and asserts his right to commissions based on a contract signed in 2011 [2]. - Olin Biotechnology disputes the claims, stating that the plaintiff's assertions lack sufficient factual and legal basis and emphasizes its commitment to defend its rights [2]. Financial Impact - The court has frozen 19.2 million yuan from one of the company's non-basic bank accounts, which represents 2.06% of the company's latest audited net assets and 8.57% of the consolidated cash balance [3]. - The company believes that the frozen amount is relatively small and will not significantly affect its daily operations, although the lawsuit pertains to core products [3]. - The financial implications are notable as the frozen amount exceeds the company's net profit for the first half of 2025, highlighting potential pressure on current performance [5]. Product and Revenue Information - Olin Biotechnology has three vaccine products on the market, two of which are related to the technical materials provided by Wang [4]. - In 2024, the Hib conjugate vaccine generated revenue of 23.5 million yuan with a gross margin of 80.9%, while the A/C group meningococcal polysaccharide conjugate vaccine generated 26.42 million yuan with a gross margin of 76.9% [4]. - The company reported a total revenue of 58.89 million yuan in 2024, marking an 18.69% year-on-year increase, with a net profit of 20.76 million yuan, also reflecting an 18.24% increase [4].

Group 1 - The core viewpoint of the article is that Olin Bio (688319.SH) has signed a supplementary agreement with Keyuan Trading to optimize the effective period of their original market promotion service agreement for the A group and C group meningococcal polysaccharide conjugate vaccine [1] - The supplementary agreement was reached based on a mutual assessment of the market environment and aims to deepen a stable and long-term cooperative relationship between the two parties [1] - Other core terms of the original agreement remain unchanged despite the optimization of the effective period [1]

Group 1 - The core viewpoint of the article is that Olin Bio (688319.SH) has signed a supplementary agreement with Keyuan Trading to optimize the effective period of their original market promotion service agreement for the A group and C group meningococcal polysaccharide conjugate vaccine [1] - The supplementary agreement was reached based on mutual assessment of the market environment and aims to deepen a stable and long-term cooperative relationship between the two parties [1] - Other core terms of the original agreement remain unchanged despite the optimization of the effective period [1]

Core Viewpoint - Oulin Biotech is facing a lawsuit involving a contract dispute with an individual, Wang Jianhua, over a total amount of 19.2 million yuan, which includes penalties and is currently under court proceedings [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Wang Jianhua is entitled to a commission of 16 million yuan for providing technical materials related to specific vaccines, along with a penalty of 3.2 million yuan calculated at 20% of the commission [3]. - Oulin Biotech has acknowledged receipt of the legal documents and asserts that the claims lack sufficient factual and legal basis, thus rejecting the plaintiff's demands [3][4]. Group 2: Financial Impact - The court has frozen 1 non-basic bank account of the company, with the frozen amount of 19.2 million yuan representing 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [4]. - The company reported a revenue of 589 million yuan in 2024, marking an 18.69% year-on-year increase, and a net profit of 20.76 million yuan, up 18.24% from the previous year [5]. Group 3: Company Background - Oulin Biotech specializes in the research, production, and sales of human vaccines and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in June 2021 [5]. - The company has only three commercialized products and has experienced significant profit declines in 2022 and 2023, with net profits dropping by 75.38% and 33.94%, respectively [5].

Core Viewpoint - Oulin Bio (688319) is facing a lawsuit regarding a contract dispute with individual Wang Jianhua, involving a total claim amount of 19.2 million yuan, which includes penalties but excludes litigation costs [1][2]. Group 1: Lawsuit Details - The lawsuit stems from a contract signed in 2011, where the plaintiff claims to have fulfilled obligations by providing two vaccine technologies and is thus entitled to a commission [1]. - Wang Jianhua's claims include a request for 16 million yuan in product commissions, 3.2 million yuan in penalties, and coverage of all litigation costs [1]. Group 2: Company Response - Oulin Bio has acknowledged receipt of legal documents and asserts that the plaintiff's claims lack sufficient factual and legal basis, thus rejecting the claims [2]. - The company emphasizes that the products involved in the lawsuit are legally marketed and compliant with relevant laws and regulations, indicating no significant adverse impact on its operations [2]. Group 3: Financial Impact - The court has frozen one non-basic bank account with a total of 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [2]. - The lawsuit's financial implications remain uncertain until the court reaches a decision, and the company will handle financial reporting in accordance with accounting standards [3]. Group 4: Commitment to Compliance - Oulin Bio, as an innovative technology company, emphasizes its commitment to intellectual property compliance and the regulation of technology cooperation, stating that all R&D activities adhere to legal requirements [3].

Core Viewpoint - Oulin Biotech's stock has shown significant volatility, with a year-to-date increase of 136.79% and a recent decline of 2.03% on December 2, 2023, indicating fluctuating investor sentiment in the biotech sector [1] Company Performance - Oulin Biotech reported a revenue of 507 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 31.11% [2] - The net profit attributable to the parent company reached 47.48 million yuan, marking a substantial increase of 1079.36% compared to the previous year [2] - The company has distributed a total of 15.43 million yuan in dividends since its A-share listing [3] Stock Market Activity - As of December 2, 2023, Oulin Biotech's stock price was 25.10 yuan per share, with a market capitalization of 10.189 billion yuan [1] - The stock has experienced a trading volume of 49.39 million yuan with a turnover rate of 0.48% [1] - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) twice this year, with the most recent occurrence on August 20 [1] Shareholder Information - As of September 30, 2025, Oulin Biotech had 10,200 shareholders, an increase of 56.42% from the previous period [2] - The average number of circulating shares per shareholder decreased by 36.07% to 39,746 shares [2] - Notable institutional shareholders include 兴全合润混合A and 兴全合宜混合A, with stable holdings compared to the previous period [3]